Sjögren’s Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient
In this report, we present a patient with metastatic non-small cell lung cancer who developed Sjögren’s syndrome secondary to immune checkpoint inhibition. This patient had a typical clinical presentation as well as biochemical signature, developing only 18 months after the start of treatment with P...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://beta.karger.com/Article/FullText/532098 |